CHENGDU, China , Aug. 27, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced its interim results for the first half of 2024, along with a corporate update. 

Rapid development of our pipeline products

Stapokibart (CM310) (IL-4Rα antibody)

• In June 2024, the long-term efficacy and safety data from the Phase III...